José A. Luchsinger on Muck Rack

José A. Luchsinger

As seen in: Alzheimer Disease & Associated Disorders, Color Research & Application, Wiley Online Library, Taylor & Francis Online, JAMA Internal Medicine Author Interviews, The Lancet, Mary Ann Liebert, Inc., RAND Corporation, Neurology, Diabetes Care Magazine, Texas Medical Center and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with José A.

Contact José A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes

|
By José A. Luchsinger
| JAMA Internal Medicine Author Interviews
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial Supplement 1. Supplement 2. eTable 1. Regression coefficients and p-values from linear models relating demographic variables with cognitive outcomes at year 4 eTable 2. Linear regression coefficients, 95% confidence intervals, and p-values from models of the GRADE primary glycemic outcome by year 4 on year 4 cognitive outcomes eTable 3.
Open in Who Shared Issue with article?

"Urinary Metal Levels, Cognitive Test Performance, and Dementia in the " by Arce Domingo-Relloso, Katlyn E McGraw et al.

|
By Arce Domingo-Relloso, Katlyn E. McGraw, Susan R. Heckbert, José A. Luchsinger
| Texas Medical Center
IMPORTANCE: Metals are established neurotoxicants, but evidence of their association with cognitive performance at low chronic exposure levels is limited. OBJECTIVE: To investigate the association of urinary metal levels, individually and as a mixture, with cognitive tests and dementia diagnosis, including effect modification by apolipoprotein ε4 allele (APOE4).
Open in Who Shared Issue with article?

Call for effective therapies for preventing dementia in people with type 2 diabetes

|
By José A. Luchsinger, Lenore J. Launer, Mark WJ Strachan, Tali Cukierman-Yaffe
| The Lancet Verified
Type 2 diabetes imposes a substantial personal and public health burden that increases with age. Globally, one in five people aged 65–99 years (136 million) live with diabetes, and this number is projected by the International Diabetes Federation (IDF) to reach 195 million by 2030 and 276 million by 2045.
Open in Who Shared Issue with article?
See all 11 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified